



Please sign a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Submitted for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>				<i>Complete if Known</i>	
				Application Number	10/045,292
				Filing Date	18-Oct-2001
				First Named Inventor	Stuyver, Lieven J. <i>et al.</i>
				Group Art Unit	N/A
Sheet	1	of	1	Attorney Docket Number	PHA 1020 US

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY
		Office ³	Number	Kind Code ² (if known)		
TM	AA	WO	9818324		Loeb, L. A.; Mullins, J.I; Univ. Washington	07.05.98
TM	AB	JP	61-130299		Daikin Kogyo	18.06.86
TM	AC	WO	01/60315A		BioChem Pharma	23.08.01
TM	AD	WO	02/18404A		Hoffmann La Roche	07.03.02

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
TM	AE	LOCKSHIN, Arnold <i>et al</i> ; "Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells", Cancer Treatment Reports (July/August 1985), 69 (7-8), 845-9			
TM	AF	DOLLINGER, Malin R. <i>et al</i> : "Analogs of 1-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies", Biochemical Pharmacology (1967), 16(4), 689-706			
TM	AG	HOSHINO, Jiro, <i>et al</i> : "Suppression of nuclear ADP-ribosyltransferase activity in Ehrlich ascites tumor cells by 5-azacytidine and its analogs", Biochemical and Biophysical Research Communications (Jan. 1987), 142(2), 468-7			

Examiner Signature	/Traviss McIntosh III/ (12/27/2006)	Date Considered	12/27/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Submitted for form 1449/PTO <i>J.C.</i> INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/045,292
				Filing Date	18 October 2001
				First Named Inventor	<i>Stuyver, L.J. et al</i>
				Group Art Unit	
Sheet	1	of	3	Attorney Docket Number	08841.105024

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
TM	AA	ALI <i>et al.</i> , <u>Tetrahedron Letters</u> , 1990, 31, 1509, Pergamon Press, Great Britain.	
TM	AB	CHU <i>et al.</i> , <u>J. Heterocycl. Chem.</u> , 1980, 17, 1435.	
TM	AC	DUSCHINSKY <i>et al.</i> , <u>J. Med. Chem.</u> , 1967, 10, 47.	
TM	AD	HUANG, G.-F. <i>et al.</i> <u>J. Carbohyd. Nucleosides Nucleotides</u> , 1978, 5, 317.	
TM	AE	IKEHARA, M. <i>et al.</i> <u>Chem. Pharm. Bull.</u> , 1967, 15, 94.	
TM	AF	KABAT <i>et al.</i> , <u>J. Med. Chem.</u> , 1987, 30, 924.	
TM	AG	KANEKO, M. <i>et al.</i> <u>Chem. Pharm. Bull.</u> 1972, 20, 635.	
TM	AH	KAZIMIERCZUK, Z. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1984, 106, 6379.	
TM	AI	LEE, W. W. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1961, 83, 1906.	
TM	AJ	LIN, T. S. <i>et al.</i> <u>J. Med. Chem.</u> , 1991, 34, 693.	
TM	AK	LOHMANN, V. <i>et al.</i> <u>Virology</u> , 108, 1998, Academic Press.	
TM	AL	MARUMOTO, R. <i>et al.</i> <u>Chem. Pharm. Bull.</u> 1974, 22, 128.	
TM	AM	MENDEZ, E. <i>et al.</i> <u>J. Virol.</u> 1998, 72, 4737.	

Examiner Signature	/Traviss McIntosh III/ (12/27/2006)	Date Considered	12/27/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/045,292
				Filing Date	18 October 2001
				First Named Inventor	Stuyver, L.J. et al
				Group Art Unit	
Sheet	2	of	3	Attorney Docket Number	08841.105024

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
TM ✓	BA	NIEDBALLA, U. <i>et al.</i> <u>J. Org. Chem.</u> , 1976, 41, 2084		
TM ✓	BB	OZOLS, A. M. <i>et al.</i> <u>Synthesis</u> , 1980, 557.		
TM ✓	BC	PANKIEWICZ, K. W. <i>et al.</i> , <u>Carbohydr. Res.</u> , 1984, 127, 227.		
TM ✓	BD	PANKIEWICZ, K. W. <i>et al.</i> , <u>Nucleosides & Nucleotides</u> , 1991, 10, 1333.		
TM ✓	BE	ROBERTS, M. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1952, 74, 668.		
TM ✓	BF	SERGUEEVA, Z. A. <i>et al.</i> <u>Nucleosides Nucleotides Nucleic Acids</u> , 2000, 19, 275.		
TM ✓	BG	SHI <i>et al.</i> , <u>J. Med. Chem.</u> , 1999, 42, 859.		
TM ✓	BH	STAVBER, S. <i>et al.</i> <u>J. Chem. Soc. Chem. Commun.</u> , 1983, 563.		
TM ✓	BI	SUHADOLNIK, R. J. <i>et al.</i> <u>Carbohydr. Res.</u> , 1978, 61, 545.		
TM ✓	BG	TANAKA, H. <i>et al.</i> <u>Chem. Pharm. Bull.</u> , 1983, 31, 787.		
TM ✓	BH	TANAKA, H. <i>et al.</i> <u>Tetrahedron Lett.</u> , 1979, 4755.		
TM ✓	BI	THURBER, T. C. <i>et al.</i> <u>J. Am. Chem. Soc.</u> , 1973, 95, 3081.		
TM ✓	BJ	THURBER, T.C. <i>et al.</i> <u>J. Org. Chem.</u> , 1976, 41, 1041.		
TM ✓	BK	TOWNSEND, L. B. <i>et al.</i> <u>Nucleic Acid Chem.</u> , 1978, 1, 272 and 343.		

Examiner Signature	/Traviss McIntosh III/ (12/27/2006)	Date Considered	12/27/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				 <p>MAR 21 2002 INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. TRADEMARK OFFICE</p>	
Sheet	3	of	3		
				Application Number	10/045,292
				Filing Date	18 October 2001
				First Named Inventor	Stuyver, L.J. et al
				Group Art Unit	
				Attorney Docket Number	08841.105024

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
TM ✓	CA	VORBRUGGEN, H. et al. <u>Chem. Ber.</u> , 1981, 114, 1234.		
TM ✓	CB	WALTON, E. et al. <u>J. Am. Chem. Soc.</u> , 1964, 86, 2952.		
TM ✓	CC	WATANABE, "The Chemistry of C-Nucleosides", TOWNSEND, L. B., Ed., In <u>"Chemistry of Nucleosides and Nucleotides"</u> , Plenum Publ., New York, Vol., 3, 421, 1994		

2323214

Examiner Signature	/Traviss McIntosh III/ (12/27/2006)	Date Considered	12/27/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.